In the 2016 WHO classification of CNS tumors, significant modifications were added when mutations in the gene encoding isocitrate dehydrogenase (IDH) and alterations in Histone 3 were recognized as characteristic in diagnoses; therefore, these were adopted as decisive markers for classifying gliomas [3,4]. This evidence concerns the gene IDH2 and central nervous system cancer.